ArticleFrontiers in oncology2025
Dose-escalated icotinib in frail, older adults patients with
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The therapeutic potential of dose-escalated EGFR-TKIs in high-risk Methods: A single-center retrospective cohort analysis included 17 treatment-naïve patients with locally advanced/metastatic Results: The study cohort, characterized by high-risk features including a median age of 73 years, poor performance status (ECOG PS 2 in 88.2% of patients), baseline brain metastases (41.2%), and multi-organ involvement (≥2 metastatic sites in 47.1%), demonstrated clinically significant antitumor activity. The objective response rate (ORR) was 52.9% (95% confidence interval [CI]: 27.8%-77.0%), while the disease control rate (DCR) reached 94.1% (95% CI: 71.3%-99.9%). Survival analyses revealed a median progression-free survival (PFS) of 14.6 months (95% CI: 2.63-26.58) and a median overall survival (OS) of 30.9 months (95% CI: 20.63-41.18). Notably, molecular stratification identified a significant survival advantage for Conclusion: Double-dose icotinib shows robust efficacy and manageable toxicity in high-risk older adults patients, with clinically meaningful PFS/OS. The unexpected OS benefit in L858R mutants warrants validation but suggests a dose-dependent advantage. Metastatic burden remains a key prognostic factor. These findings support dose escalation as a viable strategy for frail populations with limited access to next-generation TKIs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.